Osteoporosis Treatment Guidelines

First-Line Treatment

The American College of Physicians recommends bisphosphonates as the first-line pharmacologic treatment for osteoporosis, with alendronate, risedronate, and zoledronic acid being the preferred agents to reduce hip and vertebral fractures 1
For postmenopausal women with osteoporosis, oral bisphosphonates (alendronate or risedronate) or intravenous zoledronic acid should be prescribed as initial therapy to reduce the risk of hip, vertebral, and nonvertebral fractures (strong recommendation, high-certainty evidence) 2, 1
Alendronate dosing is recommended at 70 mg once weekly or 10 mg daily 3
Risedronate dosing is recommended at 35 mg once weekly, 5 mg daily, 75 mg on two consecutive days per month, or 150 mg monthly 3
Zoledronic acid dosing is recommended at 5 mg IV annually for treatment 3
Treatment duration should be 5 years initially, after which reassessment of fracture risk determines whether to continue or take a drug holiday (strong recommendation, moderate-certainty evidence) 2, 4

Denosumab 60 mg subcutaneously every 6 months is recommended as second-line therapy for patients with contraindications to bisphosphonates or who experience adverse effects from bisphosphonates (conditional recommendation, moderate-certainty evidence) 1, 5
For postmenopausal women, denosumab is conditionally recommended with moderate-certainty evidence 1
For men, denosumab is conditionally recommended with low-certainty evidence 5
Critical warning: Denosumab discontinuation causes rebound bone loss and multiple vertebral fractures—patients must transition to bisphosphonate therapy after stopping denosumab (high-certainty evidence) 1, 6

For patients at very high risk for fracture, anabolic agents should be considered before or instead of antiresorptive therapy (conditional recommendation, low-certainty evidence) 1
Very high risk is defined as: age >74 years, recent fracture within 12 months, multiple prior osteoporotic fractures, T-score ≤-3.0, fractures despite ongoing bisphosphonate therapy, or high FRAX scores 7
Teriparatide 20 mcg subcutaneously daily for up to 24 months reduces vertebral fractures by 69 per 1000 patients and any clinical fractures by 27 per 1000 patients (high-certainty evidence) 7
Romosozumab is conditionally recommended for very high-risk postmenopausal women (limited to 12 monthly doses due to waning anabolic effect) 1
Mandatory sequential therapy: After completing anabolic therapy, patients must transition to bisphosphonate or denosumab to maintain bone density gains and prevent rapid bone loss (high-certainty evidence) 1, 7

The American College of Physicians strongly recommends against using estrogen therapy, estrogen plus progestogen, or raloxifene for osteoporosis treatment (strong recommendation against, moderate-quality evidence) 2, 4, 8
These agents carry unfavorable risk-benefit profiles including cardiovascular events, thromboembolic complications, and stroke (moderate-quality evidence) 8

All patients should receive adequate calcium (1000-1200 mg daily) and vitamin D (800-1000 IU daily) supplementation throughout osteoporosis treatment (strong recommendation, high-certainty evidence) 3, 9, 10

The American College of Physicians recommends prescribing generic bisphosphonates whenever possible rather than brand-name medications, as they are significantly less expensive than other osteoporosis therapies while maintaining equivalent efficacy (strong recommendation, high-certainty evidence) 1, 4

After 3-5 years of bisphosphonate therapy, patients at low-to-moderate fracture risk should be considered for a drug holiday, while high-risk patients should continue treatment for up to 10 years (oral) or 6 years (intravenous) before reassessment, as recommended by the American College of Physicians, based on evidence from the Annals of Internal Medicine 11

Reassess fracture risk periodically (annually or biannually) during the drug holiday period, as suggested by the American College of Physicians, based on evidence from the Annals of Internal Medicine 11
Evaluate for new fractures clinically during the drug holiday period, as recommended by the American College of Physicians, based on evidence from the Annals of Internal Medicine 11

Do not implement drug holidays without risk stratification—fracture risk must be reassessed before discontinuation, as emphasized by the American College of Physicians, based on evidence from the Annals of Internal Medicine 11
Do not confuse denosumab with bisphosphonates—denosumab causes severe rebound bone loss and multiple vertebral fractures upon discontinuation and should NOT have drug holidays, as warned by the American College of Physicians, based on evidence from the Annals of Internal Medicine 11